News : For Immediate Press Release

Salius Pharma Expands Chronic Care API Portfolio Across Major Latin American Markets

“Growth strategy cantered in Argentina, Peru, Chile, Honduras, Guatemala, Bolivia and Costa Rica”

Mumbai, India – May 25, 2025

As part of a strategic effort to deepen its foothold in the Latin American market, Salius Pharma, a world-renowned supplier of high-grade pharmaceutical APIs (Bulk Drugs), has expanded its presence into the chronic therapeutic space across seven high-potential economies: Argentina, Peru, Chile, Honduras, Guatemala, Bolivia, and Costa Rica. This growth addresses the increasing demand for low-cost, high-purity Active Pharmaceutical Ingredients (APIs) used in managing diabetes, cardiovascular diseases, hypertension, and neurological disorders, which are rapidly rising in these regions due to demographic shifts and urban health challenges.

“Our growth is driven by the urgent need for affordable and reliable chronic care APIs in Latin America,” noted a senior executive at Salius Pharma.

“We are fully committed to supporting local generic pharma formulators and manufacturers with a consistent supply and regulatory-ready documentation.”

Enlarged API Portfolio for Chronic Diseases

Salius Pharma will concentrate on the supply of chronic segment APIs, such as:

• Cardiovascular : Atorvastatin, Rosuvastatin, Simvastatin, Telmisartan, Amlodipine, Losartan Potassium, Hydrochlorothiazide.
  
  
• Antidiabetic : Metformin HCl, Glimepiride, Sitagliptin, Saxagliptin, Vildagliptin, Empagliflozin.
  
  

• Neurology/CNS : Gabapentin, Pregabalin, Duloxetine, Escitalopram, Quetiapine Fumarate, Donepezil HCl and Memantine Hydrochloride.

All APIs are manufactured in WHO-GMP-certified plants across India, accompanied by complete regulatory documentation including DMFs, CEPs, and CTD dossiers, facilitating quick market entry and streamlined registration with Latin American regulatory authorities.

Strategic Market Penetration

Salius Pharma has targeted Argentina, Peru, and Chile as mature, regulation-based markets with high chronic disease burden. Honduras, Guatemala, and Costa Rica, on the other hand, are emerging pharmaceutical centres with growing local manufacturing capacity and demand for stable API partners.

To support this growth, the company is:

• Strengthening local distribution alliances.

• Participating in government tenders and public health procurement.

• Attending regional pharma industry trade shows and regulatory conferences.

“By combining technical expertise with strong local support, we aim to become the preferred API supplier for chronic disease treatments in Latin America,” the spokesperson added.

Media Contact:

Salius Pharma Pvt. Ltd.

 Email: info@saliuspharma.com

 Website: https://saliuspharma.com

Phone: +91-8425880640